About Us

Who is leading TACT2?

Gervasio Lamas, MD bioGervasio Lamas, MD

Dr. Lamas is the Chairman of Medicine at Mount Sinai Medical Center and Chief of the Columbia University Division of Cardiology at Mount Sinai Medical Center. His interests include the treatment and prevention of cardiovascular disease. During the last decade, he has enrolled thousands of patients in more than a dozen U.S. and international trials in order to improve cardiac care and prevent death and disability from heart disease. He served as Chairman of the Mode Selection Trial in Sinus Node Dysfunction (MOST), a trial that revolutionized cardiac pacemakers. He has served as Co-Chairman for the Occluded Artery Trial (OAT), and Study Chair for the Trial to Assess Chelation Therapy (TACT), a $30 million trial sponsored by the National Institutes of Health. He has authored over 300 scientific publications, and maintains an active clinical practice in Miami Beach and Key Biscayne.

Kevin Anstrom, PhD bioKevin Anstrom, PhD

Dr. Kevin Anstrom is a professor in the Department of Biostatistics and the Director of the Collaborative Studies Coordinating Center. Dr. Anstrom earned graduate degrees in biostatistics and statistics and has more than 25 years of experience in the application of statistical methods for clinical trials and observational studies. He has led multiple NIH-funded coordinating centers on projects focused on improving outcomes for patients with cardiovascular diseases, pulmonary disease, and COVID-19. Currently, he serves as DSMB Chair for a National Institute of Eye Disease funded clinical trial, and he is a member of the Steering Committees for the RECOVER-CT, HERO, and VICTOR research programs. Dr. Anstrom has a long history of mentorship with clinical trainees and other graduate students. Prior to joining the UNC faculty, he was a member of the Duke Clinical Research Institute (DCRI) including from 2002 to 2022 as a faculty member in the Department of Biostatistics and Bioinformatics. From 2018 until 2022, he was the Faculty Director of Biostatistics at the DCRI.

Daniel B. Mark, MD, MPH - bioDaniel B. Mark, MD, MPH

Dr. Mark is a clinical cardiologist and Professor of Medicine as well as Vice Chief for Academic Affairs in the Division of Cardiology, Department of Medicine at Duke University Medical Center, where he has been on the full-time faculty since 1985. He is also the Director of Outcomes Research at the Duke Clinical Research Institute. Dr. Mark's major research interests include economic and quality of life consequences of cardiovascular disease and its therapies, outcomes research, and comparative effectiveness analyses. Currently, Dr. Mark is directing a number of outcomes analyses for ongoing NIH-funded clinical trials including PROMISE, CABANA, ISCHEMIA, GUIDE-IT, and STICHES. He has authored over 305 peer-reviewed articles, two books, and 80 book chapters, and he is Editor of the American Heart Journal.